Dr. Jyoti Srivastava | Moffitt Cancer Center | United States
Dr. Jyoti Srivastava, Senior Research Scientist in the Department of Tumor Microenvironment and Metastasis at Moffitt Cancer Center, is an accomplished molecular biologist with over 18 years of pioneering experience spanning cancer biology, immuno-oncology, and therapeutic discovery. Her multidisciplinary research integrates molecular genetics, pharmacology, redox biology, and genomics to uncover mechanisms driving tumor progression, metastasis, and drug resistance. At Moffitt, Dr. Srivastava has made groundbreaking discoveries in melanoma, elucidating how redox and nitrosylation signaling pathways modulate immune evasion and therapeutic resistance in NRAS-driven cancers. Her work has identified actionable targets and led to the development of innovative RNAi-, PROTAC-, and small-molecule–based therapeutics that have advanced toward preclinical and clinical evaluation. Previously at Arrowhead Pharmaceuticals and Yale University, she spearheaded translational research programs that delivered clinical candidates for lung diseases and cancer, while uncovering novel oncogenic pathways such as AEG-1/MTDH in hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH). Dr. Srivastava’s contributions—reflected in over 30 peer-reviewed publications, invited talks at major international conferences, and successful therapeutic innovations—underscore her leadership in bridging fundamental discoveries with clinical application, advancing next-generation strategies to combat cancer and chronic diseases.
Profiles: Google Scholar
Featured Publications
Yoo, B. K., Santhekadur, P. K., Gredler, R., Chen, D., Emdad, L., Bhutia, S., … & Fisher, P. B. (2011). Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. Hepatology, 53(5), 1538–1548. https://doi.org/10.1002/hep.24221
Santhekadur, P. K., Das, S. K., Gredler, R., Chen, D., Srivastava, J., Robertson, C., … & Fisher, P. B. (2012). Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through a novel pathway involving NF-κB and miR-221. Journal of Biological Chemistry, 287(17), 13952–13958. https://doi.org/10.1074/jbc.M111.323899
Sarkar, D., & Fisher, P. B. (2013). AEG-1/MTDH/Lyric: Clinical significance. Advances in Cancer Research, 120, 39–74. https://doi.org/10.1016/B978-0-12-401676-7.00002-0
Srivastava, J., Siddiq, A., Emdad, L., Santhekadur, P. K., Chen, D., Gredler, R., … & Fisher, P. B. (2012). Astrocyte elevated gene-1 promotes hepatocarcinogenesis: Novel insights from a mouse model. Hepatology, 56(5), 1782–1791. https://doi.org/10.1002/hep.25841
Santhekadur, P. K., Akiel, M., Emdad, L., Gredler, R., Srivastava, J., … & Fisher, P. B. (2014). Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGF-β signaling. FEBS Open Bio, 4, 353–361. https://doi.org/10.1016/j.fob.2014.03.001